Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. (Q53604684)

16 May 2018

title

Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. (English)

1 reference

16 May 2018

1 reference

Barbara Orr

1

1 reference

16 May 2018

Gillian Douce

2

1 reference

16 May 2018

Susan Baillie

3

1 reference

16 May 2018

Roger Parton

4

1 reference

16 May 2018

John Coote

5

1 reference

16 May 2018

language of work or name

English

0 references

publication date

31 July 2006

1 reference

16 May 2018

number of pages

8

1 reference

inferred from page(s)

published in

Vaccine

1 reference

16 May 2018

volume

25

1 reference

16 May 2018

issue

1

1 reference

16 May 2018

page(s)

64-71

1 reference

16 May 2018

Acellular pertussis vaccines

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Immunity to Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Antibodies to Bordetella pertussis adenylate cyclase are produced in man during pertussis infection and after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Adjuvant and protective properties of native and recombinant Bordetella pertussis adenylate cyclase toxin preparations in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Bordetella pertussis adenylate cyclase toxin: proCyaA and CyaC proteins synthesised separately in Escherichia coli produce active toxin in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

Enzyme-linked immunosorbent assay for detection of pertussis immunoglobulin A in nasopharyngeal secretions as an indicator of recent infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

7 January 2021

Characterization of antibody inhibiting adherence of Bordetella pertussis to human respiratory epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

7 January 2021

Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

7 January 2021

Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

7 January 2021

CyaC-mediated activation is important not only for toxic but also for protective activities of Bordetella pertussis adenylate cyclase-hemolysin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.019

7 January 2021

10.1016/J.VACCINE.2006.07.019

Identifiers

DOI

1 reference

16 May 2018

PubMed ID

16916566

1 reference

16 May 2018